ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Individualized FAZ morphometry and standardized peri-FAZ vascular density: a pilot AngioVue OCTA study in diabetic retinopathy.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimFoveal avascular zone (FAZ) area, perimeter, acircularity, and peri-FAZ vascular density capture complementary aspects of diabetic retinopathy (DR) pathophysiology, yet their anatomical variability, geometric interdependencies, and sampling bias inherent to FD-300 measurements pose methodological challenges. This study developed AI-Plus and geometry-normalized FD-300 (nFD-300) to subsume these interdependencies and evaluated their capacity to reduce anatomical noise and improve diagnostic performance in DR staging.
methodsFAZ geometry derived from OCTA images was projected onto the FD-300 midline, integrating FAZ area (A-FAZ), perimeter (P-FAZ), and acircularity index (AI-FAZ) into a single morphometric parameter, AI-Plus, which normalized FD-300 into nFD-300. Noise-attenuation capacity was assessed via regression modelling and the delta-method. In this cross-sectional study, 256-eyes from 256-participants were evaluated: 168-treatment-naïve diabetic patients (51-NoDR, 51-mild NPDR, 66-moderate NPDR) and 88-controls. Diagnostic performance was evaluated by ANOVA, ROC analysis, and multivariable logistic regression.
resultsAI-Plus demonstrated high geometric fidelity (R²=0.962-0.984) and attenuated FAZ size variability (CV reduction: 54-78%). Controls and NoDR did not differ on any parameter. nFD-300 detected the NoDR-to-mild NPDR transition (p = 0.041), whereas FD-300 did not. nFD-300 achieved the highest diagnostic performance for controls versus mild NPDR (AUC = 0.727) and controls versus moderate NPDR (AUC = 0.833); effect size was largest for nFD-300 (η²=0.267). In multivariable models, AI-Plus absorbed P-FAZ variance and nFD-300 subsumed AI-Plus contributions (NagelkerkeR²≈0.22).
conclusionsAI-Plus provides a geometrically stable, noise-filtered, device-independent summary of FAZ morphology that substantially reduces the inter-individual variability limiting conventional metrics. By relating peri-FAZ vascular density to individual FAZ geometry, nFD-300 demonstrates discriminative sensitivity at early DR staging transitions where established parameters fall short. Neither metric requires additional imaging or acquisition time beyond routine OCTA, supporting their feasibility for prospective multicenter evaluation.
Indexed as
Identifiers
42771213What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.